Esophageal cancer
Conditions
Interventions
Tumor lysate-pulsed dendritic cells are injected on day0, day14, day28, day42, day56, day70.
Sponsors
The University of Tokyo Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Esophageal cancer patients who received curative resection and are histopathologically diagnosed as T2N0 or T3N0: -Performance status is 0-2; -20 years or more; -No serious abnormality in heart, lung, bone marrow, liver, and renal functions; -Tumor tissue is preserved after resection and tumor lysate is aseptically prepared; -MHC class1 expression on tumor tissue is detected by immunohistochemistry
Exclusion criteria
Exclusion criteria: Patients who have: -Pulmonary fibrosis or interstitial pneumonia, including their history or predisposition; -Serious drug allergy; -Difficult infections to control; -Serious cardiac diseases; -Active autoimmune diseases; -Other cancers; -Continuous systemic administration of steroids and/or immunosuppressants within 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological responses Recurrence rate Recurrence-free survival Overall survival Survival rate Response of tumor-related markers | — |
Countries
Japan
Contacts
Public ContactKazuhiro Kakimi
The University of Tokyo, Graduate School of Medicine Department of Immunotherapeutics
Outcome results
None listed